Herboxidiene and EGFR expression in A172 glioblastoma cells

Herboxidiene suppresses EGFR expression in A172 glioblastoma cells, with EGFR protein dropping to 0.30 of vehicle at 1 M while proliferation is held at or below day-0 levels.

• Why it matters: EGFR expression is a key molecular feature in glioblastoma, but it is unclear whether SF3b-inhibitor effects rely on the lung adenocarcinoma–linked intron 2 retention mechanism.
• What they did: A172 cells were treated with herboxidiene (0.125–1 M) and proliferation was tracked over 3 days versus DMSO; EGFR splicing was assessed by RT-PCR across exons 2–3 and EGFR protein by western blot.
• The result: RT-PCR showed no intron 2–retained product at any dose, while spliced EGFR decreased to 0.43 of vehicle at 0.125 M; the 170 kDa wild-type band disappeared from 0.13 M and the 190 kDa duplicated form persisted, declining gradually to 0.30 at 1 M.

AI summary of the abstract · may contain errors · not medical advice · read the paper.